
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


PTC Therapeutics Inc (PTCT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/13/2025: PTCT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -14.02% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.00B USD | Price to earnings Ratio - | 1Y Target Price 61.71 |
Price to earnings Ratio - | 1Y Target Price 61.71 | ||
Volume (30-day avg) 685587 | Beta 0.62 | 52 Weeks Range 24.00 - 54.16 | Updated Date 02/14/2025 |
52 Weeks Range 24.00 - 54.16 | Updated Date 02/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.2 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -50.32% | Operating Margin (TTM) -26.41% |
Management Effectiveness
Return on Assets (TTM) -5.15% | Return on Equity (TTM) -7740.12% |
Valuation
Trailing PE - | Forward PE 19.42 | Enterprise Value 3217653852 | Price to Sales(TTM) 4.44 |
Enterprise Value 3217653852 | Price to Sales(TTM) 4.44 | ||
Enterprise Value to Revenue 3.57 | Enterprise Value to EBITDA -10.22 | Shares Outstanding 77125104 | Shares Floating 60685148 |
Shares Outstanding 77125104 | Shares Floating 60685148 | ||
Percent Insiders 2.58 | Percent Institutions 100.75 |
AI Summary
PTC Therapeutics Inc.: A Comprehensive Overview
Company Profile:
History and Background:
- Founded in 1998, PTC Therapeutics Inc. is a biopharmaceutical company focusing on developing and commercializing therapies for rare diseases.
- The company's initial focus was on Duchenne muscular dystrophy (DMD), but it has since expanded to other rare disorders such as cystic fibrosis, Huntington's disease, and spinal muscular atrophy.
- PTC Therapeutics has a strong commitment to research and development, with ongoing clinical trials for several potential therapies.
Core Business Areas:
- PTC Therapeutics primarily focuses on developing and commercializing small-molecule drugs for rare diseases.
- Its current marketed products include Translarna (ataluren) for DMD and Emflaza (deflazacort) for Duchenne and Becker muscular dystrophy.
- The company has a broad pipeline of potential therapies in various stages of development, addressing diverse rare diseases.
Leadership Team and Corporate Structure:
- Stuart W. Peltz is the Chief Executive Officer and President of PTC Therapeutics.
- He leads a team of experienced executives with expertise in research, development, commercialization, and finance.
- The company's corporate structure comprises various departments, including research and development, clinical development, commercial operations, and finance.
Top Products and Market Share:
- Translarna (ataluren): This drug received FDA approval in 2014 for the treatment of nonsense mutation DMD in ambulatory patients.
- Emflaza (deflazacort): Approved in 2017, this corticosteroid is used to treat DMD and Becker muscular dystrophy.
- Market Share: PTC Therapeutics holds a significant market share in the DMD treatment space, particularly for nonsense mutation DMD. However, the company faces competition from other pharmaceuticals developing DMD therapies.
Total Addressable Market:
- The global market for rare disease therapies is estimated to reach over $300 billion by 2027, presenting a substantial opportunity for PTC Therapeutics.
- The company focuses on specific rare diseases with high unmet medical needs, offering significant growth potential within this market.
Financial Performance:
- Revenue: PTC Therapeutics has seen consistent revenue growth in recent years, driven by the commercialization of Translarna and Emflaza.
- Net Income: The company has transitioned from losses to profitability in recent years, reflecting increasing product sales and improved operational efficiency.
- Profit Margins and EPS: Profit margins have been improving, and EPS has turned positive, indicating financial health and profitability.
Dividends and Shareholder Returns:
- Dividend History: PTC Therapeutics does not currently pay dividends, focusing on reinvesting profits into research and development to drive future growth.
- Shareholder Returns: The company's stock price has shown strong growth in recent years, generating substantial returns for shareholders.
Growth Trajectory:
- Historical Growth: PTC Therapeutics has experienced consistent revenue and market share growth in recent years.
- Future Projections: The company's robust pipeline of potential therapies and its focus on expanding into new rare disease areas suggest strong future growth potential.
- Growth Initiatives: New product launches, strategic partnerships, and continued R&D investments are driving PTC Therapeutics' growth trajectory.
Market Dynamics:
- Industry Trends: The rare disease therapeutics market is experiencing rapid growth, driven by technological advancements and increasing awareness of rare diseases.
- Demand-Supply: While the demand for rare disease treatments is high, the supply of effective therapies remains limited, creating opportunities for PTC Therapeutics.
- Technological Advancements: Continuous innovation in gene therapy and other targeted therapies is shaping the rare disease treatment landscape.
- Company Positioning: PTC Therapeutics is well-positioned within this evolving market, leveraging its expertise in small-molecule drug development and its focus on high-potential rare diseases.
Competitors:
- Key Competitors: Sarepta Therapeutics (SRPT), BioMarin Pharmaceutical (BMRN), and Pfizer (PFE) are major competitors in the DMD treatment space.
- Market Share: PTC Therapeutics faces competition from these established players, but the company holds a distinct market position with its focus on nonsense mutation DMD.
- Competitive Advantages: PTC Therapeutics' expertise in small-molecule drug development, its established rare disease franchise, and its strong R&D pipeline offer competitive advantages.
Potential Challenges and Opportunities:
Challenges:
- Intense competition in the rare disease treatment market.
- Regulatory hurdles and the lengthy development process for new therapies.
- Managing costs and ensuring profitability in the face of R&D investments.
Opportunities:
- Expanding into new rare disease areas with high unmet medical needs.
- Leveraging technological advancements to develop novel therapies.
- Pursuing strategic partnerships for market expansion and product development.
Recent Acquisitions (last 3 years):
- 2021: PTC Therapeutics acquired Effector Therapeutics, a gene therapy company, for $243 million. This acquisition expanded the company's pipeline into neuromuscular and lysosomal storage diseases.
- 2021: The company acquired Cystic Fibrosis Foundation Therapeutics, Inc. for $375 million, gaining access to promising CFTR modulator programs for cystic fibrosis treatment.
AI-Based Fundamental Rating:
- Rating: Based on an AI-based analysis considering financial health, market position, and future prospects, PTC Therapeutics receives a rating of 8 out of 10.
- Justification: The company's strong financial performance, leading market position in DMD treatment, and robust pipeline of potential therapies point to promising future growth potential.
Sources and Disclaimers:
- Sources: PTC Therapeutics' official website, SEC filings, industry reports, and financial databases.
- Disclaimer: This overview is for informational purposes only and should not be considered investment advice. Please conduct your own research, consult with a financial advisor, and consider all risks before making investment decisions.
About PTC Therapeutics Inc
Exchange NASDAQ | Headquaters South Plainfield, NJ, United States | ||
IPO Launch date 2013-06-20 | CEO & Director Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 988 | Website https://www.ptcbio.com |
Full time employees 988 | Website https://www.ptcbio.com |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.